217326-48-2

Usage

Uses

Used in Medicinal Chemistry:
N-(3,5-Dichlorobenzenesulfonyl)-L-proline is used as a building block for the synthesis of novel drug molecules, leveraging its unique properties to create new pharmaceuticals with potential therapeutic benefits.
Used in Research and Development:
N-(3,5-DICHLOROBENZENESULFONYL)-L-PROLINE serves as a research tool in the study of the structure and function of proteins and enzymes, contributing to a deeper understanding of biological processes and aiding in the development of targeted therapies.
Used in Drug Discovery:
N-(3,5-Dichlorobenzenesulfonyl)-L-proline may be employed in drug discovery processes to identify new lead compounds or optimize existing ones, potentially leading to the creation of more effective medications.
Used in Pharmaceutical Development:
N-(3,5-DICHLOROBENZENESULFONYL)-L-PROLINE may be utilized in the development of new pharmaceuticals, where its unique properties could provide advantages in terms of efficacy, selectivity, or other desirable characteristics in treating various diseases and conditions.

InChI:InChI=1/C11H11Cl2NO4S/c12-7-4-8(13)6-9(5-7)19(17,18)14-3-1-2-10(14)11(15)16/h4-6,10H,1-3H2,(H,15,16)/t10-/m0/s1

Upstream product

• 2812-46-6 proline tert-butyl ester 
• 705-21-5 3,5-dichlorobenzensulfonyl chloride 
• 226066-04-2 1-(3,5-dichloro-benzenesulfonyl)-pyrrolidine-2-carboxylic acid tert-butyl ester 
• 147-85-3 L-proline 

Downstream Products

• 217453-65-1 (S)-3-(4-tert-Butoxy-phenyl)-2-{[(S)-1-(3,5-dichloro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid methyl ester 
• 425388-71-2 (S)-2-{[(S)-1-(3,5-Dichloro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-3-(4-hydroxy-phenyl)-propionic acid methyl ester 
• 225517-38-4 (R)-3-{[(S)-1-(3,5-Dichloro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-3-(2'-methoxy-biphenyl-4-yl)-propionic acid methyl ester 
• 225517-62-4 (R)-3-(2'-Cyano-biphenyl-4-yl)-3-{[(S)-1-(3,5-dichloro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid methyl ester 
• 929519-98-2 C₂₁H₂₂Cl₂N₂O₅S 
• 929519-99-3 C₂₁H₂₂Cl₂N₂O₅S 
• 929520-00-3 C₁₆H₂₀Cl₂N₂O₅S 
• 226066-08-6 C₂₀H₂₆Cl₂N₂O₅S 
• 226066-08-6 C₂₀H₂₆Cl₂N₂O₅S 

Relevant academic research and scientific papers

Highly constrained bicyclic VLA-4 antagonists

VLA-4 is implicated in several inflammatory and autoimmune disease states. A series of cyclic β-amino acids (β-aa) was studied as VLA-4 antagonists. Binding affinity was highly dependent on the dihedral angle (φ{symbol}) between the amino and the carboxyl

Discovery of proline sulfonamides as potent and selective hepatitis C virus NS5b polymerase inhibitors. Evidence for a new NS5b polymerase binding site

Through high throughput screening, substituted proline sulfonamide 6 was identified as HCV NS5b RNA-dependent RNA polymerase inhibitor. Optimization of various regions of the lead molecule resulted in compounds that displayed good potency and selectivity.

β-alanine derivates

Alkanoic acid derivatives of formula (1) are described: [in-line-formulae]Ar1(Alka)rL1Ar2CH(R1)C(Ra)(Ra′)R??(1)[/in-line-formulae]Ar1 is an optionally subst

Specific and dual antagonists of α4β1 and α4β7 integrins

N-(3,5-Dichlorophenylsulfonyl)-(R)-thioprolyl biarylalanine 10a has been identified as a potent and specific antagonist of the α4β1 integrin. Altering the configuration of thioproline from R to S led to a series of dual antagonists of α4β1 and α4β7, and the N-acetyl analogue 8b was found to be the most potent dual antagonist. A binding site model for α4β1 and α4β7 is proposed to explain the structure-activity relationship.

The discovery of small molecule carbamates as potent dual α4β1/α4β7 integrin antagonists

The α4β1 and α4β7 integrins are implicated in several inflammatory disease states. Systematic SAR studies of an α4β1-specific arylsulfonyl-Pro-Tyr lead led to the identification of a new α4β7 binding site, best captured by O-carbamates of Tyr for this structural class. Several compounds showed a 200- to 400-fold improvement in α4β7 binding affinity while maintaining subnanomolar α4β1 activity, for example 2l, VCAM-Ig α4β1 IC50=0.13 nM, VCAM-Ig α4β7 IC50=1.92 nM.